Securities code: 300255 securities abbreviation: Hebei Changshan Biochemical Pharmaceutical Co.Ltd(300255) Announcement No.: 2022-1 Hebei Changshan Biochemical Pharmaceutical Co.Ltd(300255)
Announcement on obtaining Bolivian drug registration certificate
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Hebei Changshan Biochemical Pharmaceutical Co.Ltd(300255) (hereinafter referred to as “the company”) recently received the drug registration certificate issued by the National Bureau of drugs and Health Technology (agemed) of Bolivia. The relevant information is hereby announced as follows: I. Basic information of drug registration documents
Drug name: enoxaparin sodium injection
Dosage form: injection
Specification: 0.4ml, 0.6ml
Drug manufacturer: Hebei Changshan Biochemical Pharmaceutical Co.Ltd(300255)
Approval date: December 14, 2021, December 6, 2021
Validity: 5 years
2、 Other relevant information of drugs
Enoxaparin sodium injection is used to prevent venous thromboembolic diseases (prevention of venous thrombosis), especially thrombosis related to orthopaedic or general surgery; Treatment of formed deep venous embolism with or without pulmonary embolism, with no serious clinical symptoms, excluding pulmonary embolism requiring surgery or thrombolytic therapy; Combined with aspirin in the treatment of unstable angina pectoris and non-Q-wave myocardial infarction; It is used in hemodialysis cardiopulmonary bypass to prevent thrombosis.
3、 Impact on the company and risk tips
Enoxaparin sodium injection has obtained the registration approval from Bolivia, which has a positive impact on the company’s expansion of overseas market. At present, the company’s overseas sales revenue of heparin preparation products accounts for a low proportion of the company’s total operating revenue. Drug sales are vulnerable to changes in overseas market policy environment, exchange rate fluctuations, market competition and other factors. Please make careful decisions and pay attention to preventing investment risks.
It is hereby announced.
Hebei Changshan Biochemical Pharmaceutical Co.Ltd(300255) board of directors January 13, 2022
